By Ian Walker
AstraZeneca said it would buy U.S.-based clinical-stage biopharmaceutical company Icosavax for up to $1.1 billion in a deal that expands its vaccines and immune therapies late-stage pipeline.
The pharmaceutical giant is offering $15 for each Icosavax share held, a 43% premium to its closing market price of $10.49 on Monday.
An extra $5.00 a share in cash could be paid depending upon certain regulatory and sales milestones being met.
Write to Ian Walker at ian.walker@wsj.com
(END) Dow Jones Newswires
12-12-23 0232ET